News

 

 

Sanovas CEO Gerrans goes linear with new MicroCam

May 2, 2013 by Arezu Sarvestani

Sanovas' new MicroCam plug-and-play endoscopic imaging system paves the way for a paradigm shift toward linear medical devices for natural orifice surgery, CEO Larry Gerrans tells MassDevice.com.

Sanovas CEO Larry Gerrans and the MicroCam technology

In talking about his company's newly launched MicroCam laparoscopic imaging platform, Sanovas CEO Larry Gerrans tells a story of innovation and, perhaps more importantly, of evolution.

In an interview with MassDevice.com, Gerrans described the "plug-&-play" MicroCam technology in terms of its ancestry in some of Sanovas' earliest technologies, speculating that the game-changing platform will help make way for the next big shift in minimally invasive procedures: Natural orifice surgery.

Sanovas' newly launched MicroCam aims to replace endoscopy carts with a tiny camera and fiberoptic wiring system, aiming to deliver the same imaging quality of a 5mm or 10mm laparoscope or bronchoscope – taking just a fraction of the space from the operating room (and the hospital's budget) in the process. Sanovas leveraged its considerable history, hailing "back to the inception of endoscopic imaging," to develop a platform Gerrans calls "far less costly than current systems, but with greater utility."

"The way we view this technology is to effectively replace the laparoscope with a variety of instruments that provide the doctor with imaging views and angles that he wants to see," he added.

The MicroCam is a tiny camera (3mm in diameter and 7.5 mm long), with a 1 mm wiring harness and a 6-inch circuit board. The system is topped off with a fiberoptic cable that can plug into nearly any OR monitor and software to "allow you to see as many MicroCams in that operating environment as you can put in it" without cluttering up an often-crowded surgical suite, Gerrans said.

The technology could also represent a cost-savings of up to 90% for hospitals paying acquisition and maintenance cost for traditional systems, he added. Sanovas has received "rapid enthusiasm" about the device and hopes to see the 1st MicroCams in hospitals in Q4 2013, or in 2014 at the latest.

"[Providers] will no longer have to pay $50,000-$130,000 for an endoscopic camera system; they can pay $10,000 for Sanovas' micro-camera technology," he said. "These hospitals spend upwards of $200,000 a year or more for their repair and maintenance of endoscopic camera technology – those are redundant costs that this technology will eliminate."

The potentially disruptive technology also helps satisfy Gerrans' desire to bring to healthcare some of the fast-paced technology leaps seen in consumer technologies.

"This relates to Moore's Law, from semiconductor technology, wherein semiconductor technology is going to get twice as fast and cost half as much every 2 years," Gerrans explained. "That law has not yet made its way to healthcare in the form of technology we provide to our providers. We see the change in paradigm of creating small, portable devices that have high capability, high utility, that can be used anywhere in an operative setting."

Sanovas MicroCam potential applications

 

Possible applications for MicroCam technology (taken from a product brochure).

But it's not just about saving money or launching sleek new technologies for Gerrans, who co-founded Sanovas in 2002. The MicroCam platform is about opening the door for a different approach to surgery.

"The prospects for this technology are innumerable, so you kind of get the mind wandering about what the future of medicine is going to look like," Gerrans told us. "What I can tell you is that 1 of our prognostications is that the future of surgery will no longer be through incisions – we see surgery being done through natural orifices."

The Sanovas technology has the potential to be ground-breaking, he said, because it's portable and plays nicely with other devices. Sanovas plans to partner with other medical device companies to integrate the MicroCam into existing surgical instruments, although Gerrans was unable to divulge the details of any partnerships due to confidentiality agreements.

"If you're an endoscopic imaging company that has an existing system that you sell or you have instruments you would like to have an eyeball on, we can put our MicroCam onto that instrument and plug it into the same monitor," he said. "There are 100s of technology companies that have therapy-enabling solutions for endoscopic applications. Those companies will certainly benefit from being able to put eyeballs on their instrumentation."

The MicroCam platform also has the potential to bring minimally invasive procedures to rural settings and emerging markets that may not have the resources to purchase more expensive cart-based endoscopic systems, or in conditions where the technology must be portable in order to reach the patient in a non-OR setting.

"When you view this technology in terms of its capability, its capability is to manifestly change the way endoscopic camera systems are used and afforded," Gerrans said. "We're obviously very excited about the development and we think this is a fundamental change to minimally invasive surgery."

Gerrans couldn't help but speculate about that future and the role that the MicroCam and other coming technologies may play in changing the nature of minimally invasive procedures. Natural orifice surgery, which involves initial entry to the body via a natural opening such as the bladder, the mouth or the colon, is not a new idea, but it's not yet widespread in practice.

"The ability to perform surgery through natural orifices will only provide you with a single track," Gerrans said. "You only have 1 approach, so you need to create new technologies that operate in a linear fashion."

"This is what we believe is an enabling technology to the growth of natural orifice surgery, it really is," he added. "It's an enabling technology to the growth and expansion of natural orifice surgery."

OEM Platform Promises To Revolutionize Endoscopic Imaging Market [View Brochure | Go to Micro Imaging Home]

SAUSALITO, Calif. ─ April 22, 2013 ─ Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today the launch of MicroCam™, its OEM “Plug & Play” micro imaging platform for endoscopic device applications.
 
The technology features proprietary software, electronics, sensors and optics that can provide autonomous imaging capability to most any surgical instrument. Sanovas will offer its imaging technology for integration with medical device makers’ existing portfolios; enabling them to improve their products clinical capabilities, enhance their product offerings and increase their competitive advantage. The system was developed to evolve and, eventually displace large, cumbersome and expensive cart based systems with leaner, more efficient and cost effective designs.
 
“This is significant innovation that will fundamentally transform the paradigm of endoscopy,” Sanovas CEO Larry Gerrans said. “We are delighted to offer the members of the medical device community the opportunity to re-imagine, re-invent and re-purpose the clinical capabilities of their products and technologies.”
 
The MicroCam™ is an integrated imaging platform inspired to enable a new generation of “Plug & Play” devices that eliminate the need for camera consoles, camera heads, camera couplers, light sources, fiber optic light cables, rod lens endoscopes and cart based systems. The elimination of these components may serve to recover vital space in cramped OR and sterile storage environments and further enable the portability of care into new, remote operating theatres.
 
The realization of efficiencies in system components will further serve to reduce providers’ acquisition costs of endoscopic camera systems by as much as 80% and reduce, if not completely eliminate the significant repair and maintenance expenditures that currently plague the operating budgets of health care providers’.
 
Market indicators relate that the U.S. and emerging global surgical camera markets are poised for immediate, explosive growth. According to a new report by iData Research (www.idataresearch.net), the leading global authority in medical device and pharmaceutical market research, ‘the overall U.S. video, high-tech and integrated operating room (OR) equipment market was worth $1.49 billion in 2009. This market, which experienced a strong decline during the economic recession, is expected to recover, exceeding $2 billion by 2016. The shift towards high-definition (HD) cameras and displays, improved OR efficiency and increasing surgical volumes will drive the market, particularly in the integrated OR and surgical camera segments.’
 
“As minimally invasive surgical procedures become the standard of care, globally, the MicroCam™ will vastly improve the expansion and operative capabilities of the science,” stated Gerrans. “Doctors will no longer have to struggle using one imaging source for the duration of their procedure. We can now put “eyeballs” on most any instrument and give the Doctor a wide variety of images and viewing angles.”
 
As part of the company’s commitment to synergize collaboration and expedite product development, Sanovas is extending its subject matter expertise in software, mechanical, electronic and optical engineering to its OEM partners.
 
Sanovas’ OEM Plug & Play MicroCam™ surgical camera initiative is intended to offer an immediate, meaningful solution to the industry, providers and patients and to serve as one of the cornerstones to the company’s arsenal of therapy enabling solutions.
 
About Sanovas
Sanovas, Inc., based in Sausalito, Calif., is a life science technology company developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies for unmet clinical needs. Sanovas' microsurgical technology platforms are designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Privately held, Sanovas was founded by the pioneers in minimally invasive surgery. The company has two patents issued and more than fifty multi-national patents pending.
 
Media Contacts:
 
For Sanovas
Steve Goldsmith, 415-729-9391

Miniaturized catheter designed to treat pulmonary disease

SAUSALITO, Calif. ─ January 17, 2013 ─ Sanovas Inc., a life science technology
company developing and commercializing the next-generation of micro-invasive
diagnostics, devices and drug delivery technologies, announced today that it has
filed with the U.S. Food and Drug Administration for clearance of the company’s Vas
Zeppelin™ Smart Catheter™ for the treatment of chronic pulmonary diseases and
lung cancer. The technology would be among the smallest interventional catheters
commercially available, allowing physicians to access and deliver therapy to some of
the tiniest and most remote passageways in the anatomy.

“This filing marks a significant milestone for Sanovas and beacons new opportunity for
physicians and patients alike,” Sanovas CEO Larry Gerrans said. “With one in seven
Americans suffering from chronic pulmonary disease and with lung cancer killing more
people than breast, prostate and colon cancers combined, new technologies aimed at
the earliest stages of lung disease are desperately needed.”

Worldwide, hundreds of millions of people suffer every day from chronic respiratory
diseases. According to the World Health Organization 235 million people suffer with
asthma and 64 million suffer with chronic obstructive pulmonary disease.  While Lung
cancer alone kills over one million people every year.

Existing surgical tools and technologies have long been recognized as being too
invasive and/or too risky to be implemented in standard clinical practice because of the
potential damage to the treatment site and/or post-operative complications. Sanovas is
developing a system of miniaturized technologies intended to overcome the complexity
and procedural risks associated with pulmonary intervention.

The Vas Zeppelin™ Smart Catheter System™ is being designed to provide surgeons
the first intelligent, integrated approach to operating on a breathing lung. The system
will feature a portfolio of integrated tools and sensors. The solution set is intended to
synergize access, 3D imaging, physiologic metrics, on-board diagnostics and related

therapy- enabling technologies to remove obstructions and to deliver drug and immune
therapies to targeted locations.

The Vas Zeppelin™ is the first component of the Vas Zeppelin™ Smart Catheter
System™. It is intended to offer an immediate, meaningful solution to physicians and
patients and to serve as the cornerstone to the company’s arsenal of therapy enabling
solutions. With two patents issued and more than 40 patents pending, Sanovas’ strong
intellectual property portfolio offers broad protection of the Vas Zeppelin™ Smart
Catheter System™. The company will be actively filing for clearance of its follow on
technologies over the ensuing months.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a life science technology company
developing and commercializing next-generation micro-invasive diagnostics, devices
and drug delivery technologies for unmet clinical needs. Sanovas' microsurgical
technology platform is designed to give surgeons the ability to access and visualize
previously inaccessible areas of the body; enabling them to diagnose, treat and deliver
drug and immune therapies to small diameter anatomy in entirely new ways. Privately
held, Sanovas was founded by pioneers in minimally invasive surgery. The company
has two patents issued and more than 40 multi-national patents pending.

Media Contact:

Steve Goldsmith
VP Marketing, Sanovas
415 729 9391 ext. 1023
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

SAUSALITO, Calif., Dec. 3, 2012 /PRNewswire via COMTEX/ -- Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, and the World Association of Bronchology & Interventional Pulmonology (WABIP) today announced that they have launched a joint research project entitled "The Breathing Innovation Survey - We Are Listening." The global initiative, being conducted via multiple surveys over the next year, will gauge the needs, opinions, preferences and insights of more than 15,000 thoracic surgeons, interventional pulmonologists and broncho-esophageal specialists.

"Providing truly innovative patient care requires that we, in the medical community, work together across specialties to prevent and treat disease particularly in the area of chronic pulmonary diseases, which affect hundreds of millions of people worldwide," said Dr. Henri Colt, M.D, Chairman of WABIP.

The one-year study will acquire and aggregate a host of data sets about the causes, distribution, and control of chronic pulmonary diseases, and is expected to provide vital physician preference and human factors data. The data will be made publicly available to researchers throughout the next few years for the purpose of advancing best practices and innovating treatment solutions that may serve to stem the global epidemic of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, cystic fibrosis, pulmonary hypertension and lung cancer.

According to the World Health Organization, hundreds of millions of people worldwide suffer daily from the effects of chronic respiratory disease, including 235 million people who have asthma and 64 million who have chronic obstructive pulmonary disease. Lung cancer alone kills more than one million people annually.

"This survey will be the first to gather extensive data across specialties about physician practice, demographic trends and treatment protocols. We expect to gain valuable insights that will directly impact treatment innovation and patient care, " said Sanovas President and CEO Larry Gerrans.

Limitations in technology and high levels of procedural risk have stymied early detection and treatment of respiratory diseases. Clinical improvements in diagnosis and intervention have long been critically needed to improve all aspects of the pulmonary science. A focus of the Breathing Innovation Survey is to advance the development of effective, economically viable solutions that may serve to improve patient care, at the local level and globally.

"As a company committed to creating highly capable, inexpensive and easy-to-use technologies for treating pulmonary disease at the bedside, whether it be in a remote village or an urban hub, Sanovas believes that these treatment limitations can be overcome," Gerrans said. "We are entering a new era where miniaturization, personalized medicine and cost efficient technologies are making what was impossible yesterday a reality today."

About WABIP

The World Association of Bronchology & Interventional Pulmonology (WABIP) is a not-for-profit medical association with central offices registered in Japan. Its role is to serve as an umbrella organization that unites national and regional bronchology associations and groups with a common purpose of enhancing patient care, research and education in bronchology and related fields.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a life science technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies for unmet clinical needs.

Sanovas' microsurgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Privately held, Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 45 multi-national patents and patents pending.

Media Contacts:

Racepoint Group For Sanovas

Marla Kertzman, 619-694-6701

SOURCE Sanovas, Inc.

Copyright (C) 2012 PR Newswire. All rights reserved

SAUSALITO, Calif., Nov. 19, 2012 /PRNewswire via COMTEX/ -- Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin(TM) Smart Catheter technology portfolio. The patent covers a unique minimally invasive system and method for delivering diagnostic and therapeutic agents to small diameter anatomy in the lungs and throughout the body.

Read more...

More Articles...

Page 1 of 6

<< Start < Prev 1 2 3 4 5 6 Next > End >>

Pulmonary Disease

Pulmonary Disease Epidemic

Sanovas is proud to present this informational video on the current epidemic of pulmonary disease and the impact it is having in the US and around the world. (click the image to view the video)

Watch Now!

Sanovas Featured on Profiles TV

Diane Feinstein

In this episode of the Profiles TV show, host Terry Bradshaw takes a look at Sanovas. The show includes interviews with Senator Dianne Feinstein, Dr. Rex Yung from Johns Hopkins University, Dr. Gerard Silvestri, President of the American Association of Bronchology and Sanovas CEO, Larry Gerrans.

Tweets from Sanovas